InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Announcements

Current share price for NUZ : $0.062 0.001 (1.64%)+

ASX company news and announcements for Neurizon Therapeutics Limited (NUZ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurizon Therapeutics Limited (NUZ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurizon Therapeutics Limited (NUZ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurizon Therapeutics Limited (NUZ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$48 Elanco representative appointed as Neurizon Board Observer 13 Aug 2026 9:46AM $0.067 $0.062 fallen by 7.46%
$48 Neurizon Completes Initial Drawdown under R&D Facility 11 Aug 2026 9:47AM $0.068 $0.062 fallen by 8.82%
$48 Appendix 4C & Quarterly Update 31 Jul 2026 3:32PM $0.057 $0.062 risen by 8.77%
$48 Neurizon Enters Strategic R&D Financing Facility 31 Jul 2026 3:21PM $0.057 $0.062 risen by 8.77%
$48 Melbourne investor briefing presentation 29 Jul 2026 1:56PM $0.060 $0.062 risen by 3.33%
$48 HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27 17 Jul 2026 9:25AM $0.063 $0.062 fallen by 1.59%
$48 Application for quotation of securities - NUZ 16 Jul 2026 11:39AM $0.066 $0.062 fallen by 6.06%
$48 Notification of cessation of securities - NUZ 14 Jul 2026 4:36PM $0.064 $0.062 fallen by 3.13%
$48 Neurizon Invites Investors to Melbourne Briefing 2 Jul 2026 9:20AM $0.060 $0.062 risen by 3.33%
$48 Change of Director's Interest Notice 1 Jul 2026 9:48AM $0.060 $0.062 risen by 3.33%
$48 Proposed issue of securities - NUZ 30 Jun 2026 9:13AM $0.059 $0.062 risen by 5.08%
$48 Notification of cessation of securities - NUZ 29 Jun 2026 4:31PM $0.059 $0.062 risen by 5.08%
$48 New NUZ-001 Mechanistic Data Presented at BIO 2026 23 Jun 2026 11:25AM $0.061 $0.062 risen by 1.64%
$48 Application for quotation of securities - NUZ 19 Jun 2026 11:15AM $0.066 $0.062 fallen by 6.06%
$48 Neurizon executes long-term supply agreement with Elanco 17 Jun 2026 9:07AM $0.063 $0.062 fallen by 1.59%
$48 HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule 12 Jun 2026 9:07AM $0.060 $0.062 risen by 3.33%
$48 Application for quotation of securities - NUZ 2 Jun 2026 5:32PM $0.063 $0.062 fallen by 1.59%
$48 Webinar presentation - Regimen I expands to 240 participants 28 May 2026 3:24PM $0.063 $0.062 fallen by 1.59%
$48 HEALEY ALS Trial Regimen I Expands to 240 Participants 27 May 2026 9:20AM $0.062 $0.062 fallen by 0%
$48 Ethics Approval Received for NUZ-001 Oral Liquid P1 Study 13 May 2026 9:19AM $0.074 $0.062 fallen by 16.22%
$48 Final Director's Interest Notice 12 May 2026 4:27PM $0.074 $0.062 fallen by 16.22%
$48 Initial Director's Interest Notice 12 May 2026 4:22PM $0.074 $0.062 fallen by 16.22%
$48 Australian Microcap Investment Conference Presentation 11 May 2026 1:20PM $0.075 $0.062 fallen by 17.33%
$48 Neurizon Strengthens Board for the Next Growth Phase 8 May 2026 9:06AM $0.075 $0.062 fallen by 17.33%
$48 Change of Director's Interest Notices 4 May 2026 12:15PM $0.081 $0.062 fallen by 23.46%

1 - 25 of 174 results

Page 1 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.